A drug-device combination bankrolled by Medtronic Inc. (NYSE:MDT) and developed by Nile Therapeutics Inc. (NSDQ:NLTX) completed dosing its first patient in Part B of an ongoing phase 1 study of cenderitide, a peptide treatment for heart failure.
Nile Therapeutics
Bacterin bounds from OTC to NYSE Amex | Funding roundup
Here’s a roundup of the latest dealflow and investment news: